Amylyx Pharmaceuticals announced Thursday it was withdrawing its approved treatment against the deadly neurodegenerative disease ALS after clinical data
Amylyx Pharmaceuticals announced Thursday it was withdrawing its approved treatment against the deadly neurodegenerative disease ALS after clinical data found no evidence the drug worked. In a statement, the US company said it would discontinue its market authorizations for Relyvrio/Albrioza, using the brand names of the medicine in the US and Canadian markets. “While this […]
The post US company withdraws ALS drug after it fails in trial appeared first on Insider Paper.
https://insiderpaper.com/us-company-withdraws-als-drug-after-it-fails-in-trial/
Comments
0 comment